Third cohort in Aptahem’s FIH study initiated
Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, announces today that the third dose cohort in the clinical First in Human (FIH) study in healthy volunteers has been initiated.
The purpose of the study is to evaluate safety and tolerability of Apta-1 in various doses.
As previously communicated, the two first dose cohorts have been approved by the authority and Aptahem’s FIH study can continue. Today the third dose cohort was initiated.
The ethics committee will review the results after each performed dose cohort and give approval for the study to continue.
For further information:
Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: ml@aptahem.com
About Aptahem
Aptahem AB (APTA) is a clinical stage biotechnology company that develops aptamer-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company’s lead candidate, Apta-1, is currently in early clinical phase. Apta-1 has in preclinical studies, by its anti-thrombotic, immunomodulating and tissue repairing characteristics, shown very positive and promising results as treatment for sepsis and critical conditions associated with sepsis. For more information, please visit www.aptahem.com